The specialists almost unanimously confirmed that the identification of disease genetic subtypes, such as those characterized by the rearrangement of core binding factors (AML-CBF), APL and AML-MRC, has a significant impact on clinical decisions. The gene discussed is CEBPZ; the disease is acute promyelocytic leukemia.